Delivery Order HHSN261201200020I-HHSN26100005
Award Date 9/18/13
Potential Completion Date 9/17/16
Potential Value $634K
Federal Agency
Awardee
Ultimate Awardee
NAICS Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Oklahoma City, OK 73104, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a federal delivery order contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to the University of Oklahoma (OU) for "OTHER FUNCTIONS - EFFICACY OF ASPIRIN AND NAPROXEN (SHORT-TERM-FREQUENT DOSING) IN COLORECTAL CANCER MODELS". The $770,757.36 contract is a cost-no-fee award that is part of the Preclinical Agent Development Assays 2012-2016 indefinite delivery/indefinite quantity (IDIQ) contract...
- This is a $819,519.17 cost-reimbursement delivery order awarded by the National Cancer Institute, a civilian agency of the U.S. Department of Health and Human Services, to the University of Oklahoma Univ Of Oklahoma Health Sciences Center Division. The order is placed under the Preclinical Agent Development Assays 2012-2016 contract vehicle and supports the development of inhibitors for MPGES-1 and 5-LOX proteins for use as colon cancer chemopreventive agents. This work is part of the agency's...
- This is a $521,214.97 Firm Fixed Price delivery order awarded by the National Institutes of Health (NIH) National Cancer Institute to the University of Oklahoma Health Sciences Center to conduct research on the chemoprevention of colorectal cancer with olmesartan medoxomil. The order is part of the NIH's PREVENT Cancer Program, which focuses on preclinical efficacy and intermediate endpoint biomarkers for cancer prevention. The delivery order does not have a set-aside designation. University...
- This is a delivery order issued under the National Cancer Institute's PREVENT Cancer Program (PREVENT) contract. The order, valued at $834,263.00, was awarded to the University of Oklahoma Health Sciences Center (OUHSC) to determine the potential clinical usefulness of aspirin and naproxen (another NSAID) for prostate cancer prevention using preclinical models. The University of Colorado-Denver is a subcontractor supporting this research. The award has a period of performance from July 2016 to...
- This is a firm fixed-price delivery order awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to the University of Oklahoma (OU) for "TARGETING CCK2R FOR PANCREATIC CANCER PREVENTION". The $474,197.46 contract is part of the NCI's Preclinical Agent Development Assays 2012-2016 program, which focuses on preclinical in vitro and in vivo agent development assays. The award does not have a set-aside designation. As...
- This is a firm fixed price Delivery Order awarded by the National Cancer Institute (NCI) to the University of Oklahoma (OU) for the "Prevention of Colorectal Cancer by ONC201" project. The contract, which is part of the NCI's "PREVENT Cancer Program", has a period of performance from September 2016 to September 2018 and a ceiling value of $221,345. The work is focused on preclinical cancer prevention research, specifically evaluating the efficacy of the drug ONC201 for...
- The federal contract award, with ID 75N91019D00020|75N91020F00003, was granted by the National Cancer Institute to the University of Oklahoma Health Sciences Center Division, a public research university in Oklahoma City, Oklahoma. The contract is for the "PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND ENDPOINT BIOMARKERS" with a task order titled "URINARY BLADDER CANCER PREVENTION WITH TWO CLINICALLY-READY AGENTS (EVEROLIMUS AND NAPROXEN) WHEN...
- This is a firm fixed-price delivery order contract awarded by the National Cancer Institute, part of the U.S. Department of Health and Human Services, to the University of Oklahoma Univ of Oklahoma Health Sciences Center Division. The $628,343 contract is for research and development related to the Preclinical Prevention Cancer Program, which focuses on preclinical efficacy and intermediate endpoint biomarkers. This work is not set aside for small businesses. The University of Oklahoma, acting...
- This is a delivery order award under the National Cancer Institute's PREVENT Preclinical Drug Development Program, a $149,995,000 indefinite-delivery, indefinite-quantity (IDIQ) contract. The award, valued at $878,817.03, is for a task order titled "Preventing Colorectal Cancer Using TRAIL-Inducing ONC201 Alone or in Combination with NSAID." The prime contractor is the University of Oklahoma Health Sciences Center, a state-funded public research university with significant federal...
- The University of Oklahoma Health Sciences Center (OUHSC) was awarded a $909,993.85 firm fixed-price delivery order by the National Cancer Institute on September 21, 2020, for the evaluation of two different classes of compounds—STAT3 inhibitors and selective estrogen receptor modulators (SERMs)—for the prevention of urinary bladder cancer. This delivery order is issued under the PREVENT Cancer Preclinical Drug Development Program, an expansive National Cancer Institute Indefinite...